Yarbrough Capital LLC Invests $382,000 in POINT Biopharma Global Inc. (NASDAQ:PNT)

Yarbrough Capital LLC purchased a new position in POINT Biopharma Global Inc. (NASDAQ:PNT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 42,130 shares of the company’s stock, valued at approximately $382,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Amundi bought a new stake in POINT Biopharma Global in the fourth quarter worth $42,000. AQR Capital Management LLC bought a new stake in POINT Biopharma Global in the fourth quarter worth $77,000. Principal Financial Group Inc. bought a new stake in POINT Biopharma Global in the second quarter worth $75,000. UBS Group AG purchased a new stake in shares of POINT Biopharma Global during the second quarter valued at approximately $77,000. Finally, Virtu Financial LLC purchased a new stake in shares of POINT Biopharma Global during the first quarter valued at approximately $92,000. Institutional investors own 59.53% of the company’s stock.

POINT Biopharma Global Stock Performance

NASDAQ:PNT traded down $0.16 during mid-day trading on Tuesday, reaching $7.19. The company’s stock had a trading volume of 76,166 shares, compared to its average volume of 621,461. POINT Biopharma Global Inc. has a 12-month low of $5.59 and a 12-month high of $11.13. The firm’s fifty day moving average price is $8.45 and its two-hundred day moving average price is $8.49. The company has a current ratio of 10.51, a quick ratio of 10.51 and a debt-to-equity ratio of 0.01. The stock has a market cap of $760.49 million, a P/E ratio of 8.45 and a beta of 0.13.

POINT Biopharma Global (NASDAQ:PNT) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.05. The firm had revenue of $4.87 million for the quarter, compared to the consensus estimate of $8.50 million. On average, equities analysts forecast that POINT Biopharma Global Inc. will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PNT shares. Raymond James set a $13.00 price objective on POINT Biopharma Global and gave the stock an “outperform” rating in a report on Monday, August 28th. Jefferies Financial Group restated a “buy” rating and issued a $14.00 price objective (up from $12.00) on shares of POINT Biopharma Global in a report on Thursday, July 20th. Finally, Piper Sandler upped their price objective on shares of POINT Biopharma Global from $14.00 to $16.00 in a report on Wednesday, June 21st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, POINT Biopharma Global currently has an average rating of “Buy” and a consensus target price of $14.33.

POINT Biopharma Global Profile

POINT Biopharma Global Inc, a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.